APM
SPRY icon

Avidity Partners Management’s ARS Pharmaceuticals SPRY Stock Holding History

Avidity Partners Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140,000
Closed -$2.44M – 65
2025
Q2 		$2.44M Buy
+140,000
New +$2.02M 0.49% 46

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Avidity Partners Management's SPRY Position: Q3 2025 in Review

Avidity Partners Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 140,000 shares — an estimated $2.44M sold.

Avidity Partners Management first reported a position in SPRY in Q2 2025 and held it in 1 quarter. The position peaked at $2.44M in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Avidity Partners Management reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Avidity Partners Management sold 140,000 ARS Pharmaceuticals shares in Q3 2025, an estimated $2.44M.
  • Avidity Partners Management first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Avidity Partners Management's ARS Pharmaceuticals position peaked at $2.44M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.